As a precursor for a pharmaceutical supply chain, it is critical for botanicals such as cannabis to be cultivated under Good Agriculture and Collection Practices (GACP). Cannabis must also be free of contaminants such as pesticides, heavy metals, microbes and aflatoxins. By controlling our own biomass supply at scale, we ensure that we always have adquate supply of clean, GACP-certified input material for extraction into Active Pharmaceutical Ingredients (APIs), and we ensure that all cannabis that we produce is safe for consumption in any form.
In addition, we farm in multiple locations – each with different terroir, sun exposure and other unique growing conditions – for the purpose of “pheno hunting” for high yielding minor cannabinoid expressions. We believe that, with more than 140 potential cannabinoids that can be present in cannabis, minor cannabinoids represent the most promising source of new molecules for the pharmaceutical industry in more than fifty years. With the proximity to the equator providing ample sunlight to support multiple harvests per year, and the extremely unique growing conditions, our farms in Jamaica have the potential to become the world’s premium source of new pharmaceutical cannabinoid molecules.